Skin disorders
23 results
Applied filters
Doxycycline and metronidazole for human and animal bites
27 November 2025SPS PGD templates for supply of doxycycline and metronidazole for the prophylaxis of human and animal bites in specified patient groups
Co-amoxiclav for human and animal bites
27 November 2025SPS PGD template for supply of co-amoxiclav for the prophylaxis of human and animal bites in specified patient groups.
Permethrin for scabies
27 November 2025SPS PGD template for supply of permethrin for the treatment of scabies in specified patient groups.
Malathion for scabies
27 November 2025SPS PGD template for supply of malathion for the treatment of scabies in specified patient groups.
The licence and supporting evidence for omalizumab biosimilar
19 September 2025We highlight evidence for licensed omalizumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Xolair).
Preparing to use omalizumab biosimilar
19 September 2025Omalizumab biosimilars are expected soon. We offer general information and implementation advice.
Using potassium permanganate for skin conditions or wound care
4 April 2025Potassium permanganate is a chemical product. We review the evidence for using it in wound care and highlight the risk of severe harm associated with wrong use.
Good governance when implementing ustekinumab biosimilar
2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use ustekinumab biosimilar
16 July 2024Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.